Influence of orally introduced silver nanoparticles on content of essential and toxic trace elements in organism

Gmoshinski, I. V.; Шумакова, А А; Шипелин, В А; Mal'tsev, G. Yu.; Хотимченко, С А

doi:10.1134/s1995078016050074

Cited by 8 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the calculation of the mass coefficients of the internal organs, a tendency of the liver weight to decrease was revealed in all experimental groups and a significant decrease in the liver mass in the 4–7.5 mg/kg groups ( p < 0.01) was observed, which might be a sign of the organ degeneration caused by the toxic doses of AgNPs-BAC. This effect might be related to the fact that the liver receives the highest amount of AgNPs circulating in the bloodstream [ 67 , 68 , 69 ]. Though the histological examination shows that none of the studied AgNP-BAC doses produced a statistically significant effect upon the mice liver, we can assume that the toxic effects were present in the groups exposed to the 4–7.5 mg/kg dose of AgNP-BAC as evidenced by the discovery of isolated infiltrates consisting of lymphocytes, macrophages and neutrophilic granulocytes.…”

Section: Discussionmentioning

confidence: 99%

In Vivo Study of Entero- and Hepatotoxicity of Silver Nanoparticles Stabilized with Benzyldimethyl-[3-myristoylamine)-propyl]ammonium Chloride (Miramistin) to CBF1 Mice upon Enteral Administration

et al. 2021

View full text Add to dashboard Cite

Silver nanoparticles (AgNPs) are the most widely studied antimicrobial nanomaterials. However, their use in biomedicine is currently limited due to the availability of data that prove the nanosilver toxicity associated primarily with oxidative stress development in mammalian cells. The surface modification of AgNPs is a potent technique of improvement of their biocompatibility. The synthetic or natural compounds that combine zero or low toxicity towards human and animal organisms with inherent antimicrobial properties are the most promising stabilizing agents, their use would also minimize the risks of microorganisms developing resistance to silver-based materials. We used a simple technique to obtain 30–60 nm AgNPs stabilized with benzyldimethyl[3-myristoylamine)-propyl]ammonium chloride monohydrate (BAC)—a well-known active ingredient of many antibacterial drugs. The objective of the study was to assess the AgNPs-BAC entero- and hepatotoxicity to CBF1 mice upon enteral administration. The animals were exposed to 0.8–7.5 mg/kg doses of AgNPs-BAC in the acute and to 0.05–2.25 mg/kg doses of AgNPs-BAC in the subacute experiments. No significant entero- and hepatotoxic effects following a single exposure to doses smaller than 4 mg/kg were detected. Repeated exposure to the doses of AgNPs-BAC below 0.45 mg/kg and to the doses of BAC below 0.5 mg/kg upon enteral administration also led to no adverse effects. During the acute experiment, the higher AgNPs-BAC dose resulted in increased quantities of aminotransferases and urea, as well as the albumin-globulin ratio shift, which are indicative of inflammatory processes. Besides, the relative mass of the liver of mice was smaller compared to the control. During the subacute experiment, the groups treated with the 0.25–2.25 mg/kg dose of AgNPs-BAC had a lower weight gain rate compared to the control, while the groups treated with the 2.25 mg/kg dose of AgNPs-BAC showed statistically significant variations in the blood serum transaminases activity, which indicated hepatosis. It should be noted that the spleen and liver of the animals from the groups treated with the 0.45 and 2.25 mg/kg dose of AgNPs-BAC were more than two times smaller compared to the control. In the intestines of some animals from the group treated with the 2.25 mg/kg dose of AgNPs-BAC small areas of hyperemia and enlarged Peyer’s patches were observed. Histological examination confirmed the initial stages of the liver and intestinal wall inflammation.

show abstract

Section: Discussionmentioning

confidence: 99%

In Vivo Study of Entero- and Hepatotoxicity of Silver Nanoparticles Stabilized with Benzyldimethyl-[3-myristoylamine)-propyl]ammonium Chloride (Miramistin) to CBF1 Mice upon Enteral Administration

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The suspension was previously characterized as containing spherical AgNP with bimodal size distribution (14.1 ± 9.9 and 50.1 ± 40.3 nm). 237 After 60 days of therapy, the sputum was negative for M. tuberculosis in 93.3% of patients enrolled in the AgNP group compared with 70% of patients who received the standard anti-TB treatment. Also, the patients enrolled in the AgNP groupshowed faster healing of the laryngeal TB-lesion, including ulcerations and voice function compared to standard tuberculosis drugs.…”

Section: In Vivo Preclinical and Clinical Studiesmentioning

confidence: 95%

<p>Silver Nanoparticles for the Therapy of Tuberculosis</p>

Tabaran

Matea²,

Mocan³

et al. 2020

IJN

View full text Add to dashboard Cite

Rapid emergence of aggressive, multidrug-resistant Mycobacteria strain represents the main cause of the current antimycobacterial-drug crisis and status of tuberculosis (TB) as a major global health problem. The relatively low-output of newly approved antibiotics contributes to the current orientation of research towards alternative antibacterial molecules such as advanced materials. Nanotechnology and nanoparticle research offers several exciting new-concepts and strategies which may prove to be valuable tools in improving the TB therapy. A new paradigm in antituberculous therapy using silver nanoparticles has the potential to overcome the medical limitations imposed in TB treatment by the drug resistance which is commonly reported for most of the current organic antibiotics. There is no doubt that AgNPs are promising future therapeutics for the medication of mycobacterial-induced diseases but the viability of this complementary strategy depends on overcoming several critical therapeutic issues as, poor delivery, variable intramacrophagic antimycobacterial efficiency, and residual toxicity. In this paper, we provide an overview of the pathology of mycobacterial-induced diseases, andhighlight the advantages and limitations of silver nanoparticles (AgNPs) in TB treatment.

show abstract

“…There seems to be no principle differences in toxic effects produced by nanomaterials based on Ni, its oxide, as well as its soluble salts (chloride, nitrate, and sulfate) on cells; so, we can conclude that it is Ni++ ions emission from them that plays the leading role in toxicity of these nanomaterials. Ni-containing nanomaterials differ substantially in this respect from those nanoparticles that are practically insoluble in biological media such as previously described nanoparticles of amorphous silicon dioxide [61] with the greatest contribution into their toxic effects being made by catalytic ROS generation on their surface; as well as partially soluble silver nanoparticles that exert intense influence on microelement homeostasis [62]. But at the same time, effective doses detected for NPs of Ni and its compounds turn out to be lower than those detected for its soluble salts and it highlights the significant role in cytotoxic effects that belongs to ability of these nanomaterials to penetrate into cells more easily.…”

Section: Molecular and Cellular Cytotoxicity Mechanisms Data Obtained Via Studies In Vitro Allow Making Well-substantiated Conclusion On mentioning

confidence: 99%

Assessing risks caused by nickel-based nanomaterials: hazardous factor identification

Gmoshinski¹,

lane²,

Хотимченко³

2021

Health Risk Analysis

View full text Add to dashboard Cite

Nanoparticles of nickel (Ni) and its compounds attract a lot of attention bearing in mind their promising innovative properties allowing their use as catalysts, components in electrical appliances, electronic devices and photonic appliances, and materials used in producing medications, diagnostic preparations, and pesticides. Production volumes of these materials in their nano-form are likely to grow rapidly in the nearest future and it involves greater loads created by these nanomaterials on a human body. And we should remember that Ni and its compounds are highly toxic for humans even in their traditional disperse forms. Their toxicity induces oxidative stress, cellular membranes and mitochondria dysfunction, expression of nuclear transcription factors that are responsible for apoptosis, caspases, as well as proto-oncogenes. Leading role in toxicity of Ni-containing nanomaterials obviously belongs to ions of heavy Ni++ being emitted from them since this heavy metal has pro-oxidant properties and influences enzyme activity and gene expression. Cytotoxic effects produced by Ni-containing nanomaterials were revealed in Model experiments in vitro performed with suing cellular cultures that were morphologically and functionally similar to epithelial cells of respiratory and gastrointestinal tract, liver, kidneys, and nervous system; these materials were able to stimulate oxidant stress, influence expression of apoptosis proteins and nuclear transcription factors, induce apoptosis and necrosis. There are data indicating that Ni-containing nanomaterials can produce malignant transforming effects in vitro. All the above mentioned proves that nickel compounds in their nanoform are a new hazardous factor that requires assessing related risks for workers, consumer, and population in general. Our review focuses on analyzing literature sources on cytotoxicity of Ni-containing nanomaterials and their effects produced on molecular-genetic and cellular levels taken over a period starting from 2011.

show abstract

Influence of orally introduced silver nanoparticles on content of essential and toxic trace elements in organism

Cited by 8 publications

References 13 publications

In Vivo Study of Entero- and Hepatotoxicity of Silver Nanoparticles Stabilized with Benzyldimethyl-[3-myristoylamine)-propyl]ammonium Chloride (Miramistin) to CBF1 Mice upon Enteral Administration

In Vivo Study of Entero- and Hepatotoxicity of Silver Nanoparticles Stabilized with Benzyldimethyl-[3-myristoylamine)-propyl]ammonium Chloride (Miramistin) to CBF1 Mice upon Enteral Administration

<p>Silver Nanoparticles for the Therapy of Tuberculosis</p>

Assessing risks caused by nickel-based nanomaterials: hazardous factor identification

Contact Info

Product

Resources

About